search
Back to results

Compassionate Use of Dupilumab

Primary Purpose

Bullous Pemphigoid, Pediatric Eosinophilic Esophagitis (EoE), Pediatric Asthma

Status
Available
Phase
Locations
Study Type
Expanded Access
Intervention
Dupilumab
Sponsored by
Regeneron Pharmaceuticals
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial for Bullous Pemphigoid

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    February 25, 2021
    Last Updated
    July 26, 2022
    Sponsor
    Regeneron Pharmaceuticals
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04776694
    Brief Title
    Compassionate Use of Dupilumab
    Study Type
    Expanded Access

    2. Study Status

    Record Verification Date
    July 2022
    Overall Recruitment Status
    Available
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Regeneron Pharmaceuticals

    4. Oversight

    5. Study Description

    Brief Summary
    Provide Compassionate Use of Dupilumab
    Detailed Description
    Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Bullous Pemphigoid, Pediatric Eosinophilic Esophagitis (EoE), Pediatric Asthma, Pediatric and Adolescent Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

    7. Study Design

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    Dupilumab
    Other Intervention Name(s)
    REGN668, DUPIXENT®, SAR231893

    10. Eligibility

    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Requests for compassionate use must be initiated by a treating physician. Physicians should contact
    Phone
    844-734-6643
    Email
    CompassionateUse_Requests@regeneron.com

    12. IPD Sharing Statement

    Learn more about this trial

    Compassionate Use of Dupilumab

    We'll reach out to this number within 24 hrs